Uncategorized

Karyopharm Slides as Mixed Myelofibrosis Results Cloud Regulatory Road

Published

2 weeks ago

on

Missing one of its co-primary endpoints could make it difficult for Karyopharm Therapeutics to score conventional approval for Xpovio in myelofibrosis, according to Jefferies analysts.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version